Allovir IncNASDAQ:ALVRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7655
- TODAY'S CHANGE (%)-0.0245 (-3.1013%)
- Bid / Lots0.7325/ 13
- Ask / Lots0.7900/ 10
- Open / Previous Close0.7663 / 0.7900
- Day Range
- 52 Week Range
- Volume469,775
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALVR |
|---|---|---|
| 09:32 ET | 356 | 0.7663 |
| 09:41 ET | 100 | 0.76835 |
| 09:57 ET | 300 | 0.7488 |
| 10:06 ET | 200 | 0.7769 |
| 10:10 ET | 1559 | 0.7698 |
| 10:12 ET | 200 | 0.7698 |
| 10:30 ET | 144 | 0.7511 |
| 10:33 ET | 300 | 0.75135 |
| 10:51 ET | 300 | 0.7516 |
| 10:53 ET | 100 | 0.77035 |
| 10:55 ET | 200 | 0.752 |
| 10:57 ET | 100 | 0.76 |
| 11:06 ET | 100 | 0.76 |
| 11:11 ET | 200 | 0.7893 |
| 11:13 ET | 400 | 0.76 |
| 11:18 ET | 1100 | 0.7516 |
| 11:20 ET | 100 | 0.7522 |
| 11:24 ET | 1800 | 0.7704 |
| 11:26 ET | 200 | 0.7517 |
| 11:27 ET | 100 | 0.7522 |
| 11:33 ET | 600 | 0.7702 |
| 11:36 ET | 100 | 0.7702 |
| 11:40 ET | 2850 | 0.7512 |
| 11:42 ET | 100 | 0.7522 |
| 11:45 ET | 500 | 0.7522 |
| 11:49 ET | 484 | 0.7522 |
| 11:51 ET | 100 | 0.7522 |
| 11:56 ET | 600 | 0.7506 |
| 12:00 ET | 627 | 0.7607 |
| 12:02 ET | 1500 | 0.7672 |
| 12:03 ET | 100 | 0.7646 |
| 12:05 ET | 1384 | 0.7672 |
| 12:09 ET | 100 | 0.76725 |
| 12:12 ET | 100 | 0.7645 |
| 12:18 ET | 100 | 0.7645 |
| 12:20 ET | 200 | 0.7646 |
| 12:23 ET | 100 | 0.7646 |
| 12:30 ET | 300 | 0.7673 |
| 12:32 ET | 200 | 0.7673 |
| 12:34 ET | 100 | 0.7647 |
| 12:39 ET | 200 | 0.7651 |
| 12:45 ET | 300 | 0.76735 |
| 12:48 ET | 300 | 0.77 |
| 12:50 ET | 100 | 0.7674 |
| 12:52 ET | 200 | 0.77 |
| 12:54 ET | 327 | 0.7674 |
| 12:56 ET | 100 | 0.7674 |
| 12:57 ET | 773 | 0.7751 |
| 01:01 ET | 100 | 0.78125 |
| 01:14 ET | 200 | 0.7779 |
| 01:30 ET | 1600 | 0.781 |
| 01:32 ET | 200 | 0.781 |
| 01:39 ET | 200 | 0.773 |
| 02:08 ET | 300 | 0.7729 |
| 02:33 ET | 100 | 0.7729 |
| 02:58 ET | 200 | 0.773 |
| 03:14 ET | 100 | 0.7852 |
| 03:36 ET | 800 | 0.7866 |
| 03:41 ET | 400 | 0.7866 |
| 03:50 ET | 300 | 0.7844 |
| 03:52 ET | 700 | 0.769 |
| 03:54 ET | 100 | 0.784 |
| 03:56 ET | 600 | 0.7847 |
| 03:57 ET | 100 | 0.784 |
| 03:59 ET | 374231 | 0.7655 |
Sep 16, 2024
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm, from 11:16AM ET on Monday Sep 16, 2024 by Dow Jones
11:16AM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allovir Inc | 91.1M | -0.6x | --- |
Hillevax Inc | 90.1M | -0.5x | --- |
Boundless Bio Inc | 95.0M | -1.7x | --- |
Benitec Biopharma Inc | 87.0M | -0.9x | --- |
Bioatla Inc | 84.1M | -0.8x | --- |
Eledon Pharmaceuticals Inc | 98.3M | -1.1x | --- |
Company Information
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Contact Information
- Headquarters
- 1100 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 617-433-2605
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- David Hallal
- President, Chief Financial Officer, Director
- Vikas Sinha
- Chief Executive Officer, Director
- Diana Brainard
- Co-Founder, Chief Scientific Officer
- Ann Leen
- Chief Accounting Officer
- Brett Hagen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $91.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 115.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-1.23 |
Book Value | $1.28 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
